Literature DB >> 8477121

Reversible seizures and mental status changes in a dialysis patient on isoniazid preventive therapy.

D S Asnis1, J G Bhat, A F Melchert.   

Abstract

OBJECTIVE: To report a case of reversible seizures and mental status changes in a dialysis patient given preventive isoniazid therapy. CASE
SUMMARY: A 66-year-old woman on continuous ambulatory peritoneal dialysis (CAPD) was given isoniazid prophylaxis following a purified protein derivative (PPD) reaction greater than 20 mm in duration. Oral administration of isoniazid 300 mg/d was started and four days later she was admitted to the hospital for confusion, lethargy, and focal seizures that began 24 hours after initiation of therapy. All medications were discontinued with the exception of oral pyridoxine 50 mg/d. Dialysis was withheld to determine if the seizures were medication induced rather than uremia related. Seizures and mental status changes were reversed with pyridoxine. Dialysis was restarted after the symptoms resolved.
CONCLUSIONS: Preventive therapy against tuberculosis with isoniazid should be stressed throughout the medical community. Isoniazid has adverse effects including hepatitis and peripheral neuropathy (common) and convulsions (rare). Our experience suggests that additional supplementation with pyridoxine 50 mg/d should be given routinely to prevent adverse reactions in uremic patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8477121     DOI: 10.1177/106002809302700410

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  2 in total

1.  Seizures caused by pyridoxine (vitamin B6) deficiency in adults: A case report and literature review.

Authors:  Yisha Tong
Journal:  Intractable Rare Dis Res       Date:  2014-05

2.  Seizures in an Immunocompetent Adult From Treatment of Latent Tuberculosis Infection: Is Isoniazid to Blame?

Authors:  Bhagyashri Navalkele; Maria X Bueno Rios; John D Wofford; Vijay Kumar; Risa M Webb
Journal:  Open Forum Infect Dis       Date:  2020-04-23       Impact factor: 3.835

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.